SlideShare a Scribd company logo
1 of 20
Morbosità e mortalità: un approccio
multicausa al fenomeno della droga
Roberta Crialesi,
Alessandra Burgio, Francesco Grippo, Marilena Pappagallo
Migliorare la comprensione del fenomeno droga:
quali dati per le politiche
Roma, 26 gennaio 2015
Istat, Aula Magna
• La riduzione della perdita di vite umane causata dal consumo di stupefacenti è una
priorità strategica delle politiche di lotta alla droga e uno degli obiettivi di salute
pubblica dell’Unione europea
• Valutare scientificamente le conseguenze dirette e indirette dell’uso di droghe non è
semplice. Nel corso degli ultimi anni, le politiche di riduzione del danno hanno
stimolato l’adozione di approcci basati su dati incontrovertibili.
• Uno degli approcci più innovativi per fornire un quadro realistico dell’impatto delle
droghe sulla salute della popolazione italiana è quello basato sulla comorbidity e
sulla cause multiple di decesso
• Occorrono indicatori innovativi per misurare, in modo più accurato, la reale
dimensione del fenomeno estendendo l’osservazione a tutti i casi, direttamente
o indirettamente, collegati all’abuso di droghe.
Elementi chiave della strategia europea di riduzione del danno
Roma, 26 gennaio 2015 2
Obiettivi dello studio
• Analizzare la mortalità indotta da droga e l’ospedalizzazione dei pazienti
tossicodipendenti per descrivere l’evoluzione nel tempo dei principali
indicatori secondo il genere, l’età e le macro aree di residenza
• Utilizzare l’approccio per cause multiple per
 fornire nuovi indicatori basati su tutte le informazioni riportate sia
nel certificato di morte sia nelle SDO
valutare statisticamente le associazioni tra l’abuso di droga e altre
condizioni patologiche
3Roma, 26 gennaio 2015
In Italy an average of 4,2 conditions are reported.
The International Classification of Diseases (Icd) contains instruction
for coding each condition and for the selection of the Underlying
cause.
Causes of Death Register
• Refers to all cases occurred in Italy
• Certifying physician reports a sequence of conditions leading to death on the death
form:
Part 1:
Line a (Underlying cause) ___________________________________
Line b (complications) ___________________________________
Line c ___________________________________
Line d ___________________________________
Part 2 (Other causes ___________________________________
Contributing) ___________________________________
Hiv infection
Kaposi’s sarcoma
Heroin dependency for many years
Pneumonia
Septicemia
Coding Each
Condition: Icd-10
codes
B24
C46
J18.9
A41.9
F11.2
SELECTION
Process
UC: B24
HIV disease
In Italy, until 2003 data only this information
was published
Traditionally, final statistics are based on
UNDERLYING CAUSE OF DEATH
One for each record defined as:
(a) the disease of injury which initiated the train
of events leading directly to death, or
(b) the circumstances of the accident or
violence which produced the fatal injury
Since 2003 data also this information
is available
MULTIPLE CAUSES OF DEATH
Specimen based on Istat D4
4
Drug-induced mortality: selection of Icd codes
(EMCDDA selction B for international comparison and time series)
ICD-10: years 2003, 2006-2011
Mental and behavioural disorders due
to psychoactive substance use
F11: opioids;
F12: cannabinoids,
F14: cocaine;
F15: other stimulants, including caffeine;
F16: hallucinogens;
F19: other psychoactive substances
Accidental poisoning
X421): narcotics and psychodysleptics [hallucinogens], not elsewhere classified;
X412antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not
elsewhere classified
Intentional self-poisoning
X621): narcotics and psychodysleptics [hallucinogens], not elsewhere classified;
X612): antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not
elsewhere classified.
Poisoning undetermined intent
Y121): psychodysleptics [hallucinogens], not elsewhere classified, undetermined
intent;
Y112): antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not
elsewhere classified, undetermined intent.
1) in combination with the T-codes: T40.0-9: Poisoning by narcotics and psychodysleptics [hallucinogens];
2) in combination with T code: T43.6 Poisoning by psychotropic drugs, Psychostimulants with abuse potential.
5
Numero di decessi droga-indotti avvenuti in Italia registrati nel database ISTAT sulle
cause di morte (popolazione presente). Anni 1980-2011 Confronto con Emcdda
6
Numerodidecessi
Trends per genere ed età Anni 1992-2011
Mortalità indotta da droghe per macroarea e anno di decesso.
Poolazione residente, anni 1992-2010. Tassi std.di mortalità per 1.000.000 abitanti
Geografia
Underlying cause of death Multiple cause of death
Ratio
Multiple/
Underlyingdeaths
crude
rate
standardiz
ed rate
deaths
crude
rate
standardiz
ed rate
15-44
year 605 0,87 816 1,18 1,3
45-54 175 0,67 398 1,53 2,3
55-64 33 0,15 79 0,36 2,4
Total 15- 64
males 692 1,19 1,17 1.115 1,91 1,84 1,6
females 121 0,21 0,20 178 0,30 0,29 1,5
Total 813 0,69 0,69 1.293 1,10 1,07 1,6
Drug-related deaths in selected age groups as
underlying and multiple cause. Years 2009-2011
Total
2006-2008
1.193 1,03 1,03 1.606 1,39 1,36 1,3
9
Methods
Age-standardized relative risk (RR) was used to measure association among drug related cause and
the other conditions reported on the death certificate
The relative risk can be seen as a measure of the strength of association of a certain cause with drug-
related condition.
)(ln96.1ln)(ln%95 RRSERRRRCI 
Assumed that RR is approximately log-normally distributed:
where
Proportion of estimated deaths with a specific condition A among those
WITH mention of drug-related cause
Proportion of estimated deaths with a specific condition A among those
WITHOUT mention of drug-related cause
Cause A
mentioned
Cause A not
mentioned
Mention of drug-related
cause
Without mention of drug-
related cause
dADˆ
Ad
Dˆ
Ad
Dˆ
Ad
Dˆ
dD
d
D
Ad
dA
d
Ad
d
dA
p
p
D
D
D
D
RR
ˆ
ˆˆ
/
ˆ

Ad
Ad
dA
dA
D
p
D
p
RRES
ˆ
)ˆ1(
ˆ
)ˆ1(
)(ln




Associations of conditions with drug-related causes.
Associations of conditions with drug-related causes.
1.293 cases, Italy 2009-2011
Icd10 Condition
Prevalence
in drug
users
deaths
Prevalence in
non-drug
users deaths
Age-
standardized
RR
CI95%
Certificates
mentioning
the
condition
among drug
users deaths
A00-B99 Infectious and parasitic diseases 23,8 9,4 3,4 3,2-3,7 308
B20-B24 AIDS 7,1 1,2 5,9 4,8-7,2 92
B15-B19,
B94.2
Viral hepatitis 18,2 2,5 10,7 9,7-11,8 235
F01-F99 Mental and behavioural disorders (excluded those included in
EMCDDA)
14,2 4,0 6,8 6,2-7,5 184
F10 Mental and behavioural disorders due to use of alcohol 9,6 0,9 17,5 15,4-20,0 124
I00-I99 Diseases of the circulatory system 40,4 48,0 1,1 1,0-1,2 522
I33 Acute and subacute endocarditis 0,9 0,1 7,0 3,9-12,6 11
I38 Endocarditis, valve unspecified 1,2 0,3 2,0 1,0-3,9 15
J00-J99 Diseases of the respiratory system 32,6 24,6 1,2 1,1-1,3 422
K00-K92 Diseases of the digestive system 22,1 16,1 1,8 1,6-1,9 286
K70, K73-K74 Cirrhosis, fibrosis and chronic hepatitis 16,2 6,2 3,6 3,2-4,0 209
K70 Alcoholic liver disease 3,3 1,3 2,7 2,0-3,6 43
K73 Chronic hepatitis, not elsewhere classified 1,1 0,2 19,5 14,3-26,7 14
R00-R99 Symptoms signs and ill-defined causes 38,6 33,6 1,1 1,1-1,2 499
R75 Laboratory evidence of human immunodeficiency virus [HIV] 1,3 0,1 9,1 5,4-15,2 17
V00-Y99 External causes of death (excluded those included in EMCDDA) 52,6 14,0 2,4 2,2-2,6 680
Roma, 26 gennaio 2015 12
Schede di Dimissione Ospedaliera (SDO)
• La diagnosi principale è utilizzata per la costruzione di indicatori statistici (come per le cause di morte)
•International Classification of Diseases 9th Revision, Clinical Modification (ICD9CM)
•Diagnosi principale e fino a 5 Diagnosi secondarie
• In media sono riportate 2.5 diagnosi per ricoveri ordinary e 1,6 per day hospital
• Le Diagnosi sono codificate direttamente in ospedale
DIAGNOSI PRINCIPALE
definita come la malattia che alla dimissione viene identificata
come la principale responsabile del trattamento e delle procedure
fornite dall’ospedale.
DIAGNOSI SECONDARIA
Definite come quelle condizioni che coesistono al momento del
ricovero o che si sviluppano in seguito a tale momento e che
influenzano il trattamento ricevuto e/o la durata della degenza
Co-morbidity approach
13
Number of hospital discharges for drug-related disorders
0
2,000
4,000
6,000
8,000
10,000
12,000
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
• From 10,968 in 1999 to 5,857 in 2012 (-46.6%)
• Sharp decrease between 1999 and 2003, smoothed afterwards
Crude
rates (a)
Standardized
rates (a)
1999 19.3 18.5
2012 9.8 10.2
(a) per 100,000 residents
Number of patients treated in outpatient facilities for drug-related disorders
14
Trends by age
Age-specific hospitalization rates for drug-related disorders per 100,000 residents
• Higher hospitalization rates in the age group 25-44 years
• followed by 15-24 years before 2009 and 45-54 years too afterwards
• Age gaps reduced over time
Roma, 26 gennaio 2015 15
Drug-related hospitalizations 15-64 years. Main diagnosis
and All diagnosis. Years 2006-2008, 2009-2011
Main diagnosis All diagnosis
Age discharges
crude
rate
discharges
crude
rate
2006-2008
15-44 13,834 19.3 40,721 56.8 2.9
45-54 2,222 9.1 8,625 35.4 3.9
55-64 811 3.8 2,653 12.4 3.3
2009-2011
15-44 11,801 16.8 32,611 46.3 2.8
45-54 3,265 12.4 9,727 36.8 3.0
55-64 1,356 6.1 3,041 13.6 2.2
Ratio
All/Main
15-64 years
Main diagnosis All diagnosis
Gender discharges
crude
rate
standardized
rate
discharges
crude
rate
standardized
rate
2006-2008
males 11,407 19.4 21.7 35,617 60.6 66.7 3.1
females 5,460 9.3 10.4 16,382 27.9 30.8 3.0
total 16,867 14.4 16.1 51,999 44.2 48.9 3.1
2009-2011
males 9,831 16.6 18.6 30,663 51.6 57.3 3.1
females 6,591 11.0 12.2 14,716 24.7 27.2 2.2
total 16,422 13.8 15.4 45,379 38.1 42.3 2.8
Ratio
All/Main
• All diagnosis:
 Decreasing std rates…
 …due to the decrease in the age group
15-44 years…
 …while rates slightly increase after 45
years of age
• Hospitalizations with
mention of drug use or
poisoning is 2.8 higher
than the number based
on the Main diagnosis
• Gender gap: std rates
higher for men (1.5
times for main diag., 2.1
times for all diag.)
16
Drug-related hospitalizations by substance (dependence, abuse or poisoning)
15-64 years - All diagnosis.
Ratios All diagnosis / Main diagnosis
0
10
20
30
40
50
2006-2008 2009-2012
Mixed or unspecified
substances
Cannabis, Amphetamine
and other psychostimulant
Cocaine
Opioid type (Heroin,
Methadone, Opium, etc.)
19,773
9,130
5,374
17,722
15,908
7,803
5,461
16,207
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2006-2008 2009-2012
Mixed or unspecified
substances
Cannabis, Amphetamine
and other psychostimulant
Cocaine
Opioid type (Heroin,
Methadone, Opium, etc.)38.0% 35.1%
17.6%
17.2%
10.3% 12.0%
34.1% 35.7%
Standardized hospitalization rates for drug-related disorders
per 100,000 residents (absolute numbers in the bars)
Ratios Males / Females
17
Associations of conditions with drug-related diagnosis (1)
ICD9CM
code Condition
Prevalence in
hospitalizations
for drug
disorders
Prevalence in
hospitalizations
NOT for drug
disorders
Age
standardized
RR CI95%
Hospital
discharge
records with
mention of the
condition
among
hospitalizations
for drug
disorders
INFECTIOUS AND PARASITIC DISEASES (001-139)
042
Human immunodeficiency virus [HIV]
disease 7.77 0.53 13.08 12.63-13.53 3,528
070 Viral hepatitis 11.38 0.76 12.55 12.19-12.91 5,162
112 Candidiasis 1.51 0.10 15.11 13.98-16.34 684
MENTAL DISORDERS (290-319)
295 Schizophrenic disorders 4.86 0.73 5.57 5.32-5.82 2,204
296 Affective psychoses 10.70 0.93 11.51 11.20-11.83 4,854
298 Other nonorganic psychoses 3.65 0.29 11.11 10.55-11.70 1,656
300 Neurotic disorders 7.75 0.87 11.42 11.10-11.74 3,518
301 Personality disorders 19.37 0.54 28.92 28.28-29.58 8,790
303 Alcohol dependence syndrome 8.31 0.33 21.81 21.08-22.57 3,772
307
Special symptoms or syndromes, not
elsewhere classified 3.35 0.27 17.08 16.36-17.82 1,520
309 Adjustment reaction 1.63 0.13 12.81 11.91-13.77 741
Roma, 26 gennaio 2015 18
Associations of conditions with drug-related diagnosis (2)
ICD9CM
code Condition
Prevalence in
hospitalizations
for drug
disorders
Prevalence in
hospitalizations
NOT for drug
disorders
Age
standardized
RR CI95%
Hospital
discharge
records with
mention of the
condition
among
hospitalizations
for drug
disorders
DISEASES OF THE NERVOUS SYSTEM AND SENSE ORGANS (320-389)
345 Epilepsy 1.68 0.63 2.57 2.39-2.76 762
346 Migraine 12.78 0.19 100.07 97.91-102.27 5,799
DISEASES OF THE CIRCULATORY SYSTEM (390-459)
401 Essential hypertension 3.12 4.70 1.33 1.29-1.38 1,417
DISEASES OF THE RESPIRATORY SYSTEM (460-519)
486 Pneumonia, organism unspecified 1.00 0.26 3.84 3.50-4.21 456
491 Chronic bronchitis 1.20 1.09 1.68 1.57-1.80 545
518 Other diseases of lung 2.34 1.16 2.24 2.12-2.37 1,062
DISEASES OF THE DIGESTIVE SYSTEM (520-579)
571 Chronic liver disease and cirrhosis 6.27 1.90 3.35 3.23-3.47 2,845
SYMPTOMS, SIGNS, AND ILL-DEFINED CONDITIONS (780-799)
780 General symptoms 2.44 1.39 1.84 1.74-1.95 1,107
INJURY AND POISONING (800-999)
965
Poisoning by analgesics, antipyretics, and
antirheumatics 2.31 0.01 313.35 288.93-339.84 1,050
969 Poisoning by psychotropic agents 1.38 0.05 28.02 25.79-30.45 627
SUPPLEMENTARY CLASSIFICATION OF FACTORS INFLUENCING HEALTH STATUS AND CONTACT WITH HEALTH SERVICES (V01-V82)
V02 Carrier or suspected carrier of infectious diseases 1.12 0.18 5.76 5.25-6.31 510
Roma, 26 gennaio 2015 19
20
Istat, Navigando tra le fonti demografiche e sociali, 2009
http://www3.istat.it/dati/catalogo/20100325_01/Navigando_tra_le_fonti_demografiche_sociali.pdf
WHO. International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision (ICD-10). Geneva: WHO; 1992.
Emcdda methods and definitions http://www.emcdda.europa.eu/stats07/DRD/methods
Istat. Cause di morte. Anno vari. http://www.istat.it/it/archivio/
Emcdda, Data, drug related death and mortality http://www.emcdda.europa.eu/stats/archive.
Istat. Cause multiple di morte. Anno 2008. http://www.istat.it/it/archivio/66021
Istat, I.Stat, Salute e sanità, Ricorso ai servizi sanitari, Ospedalizzazione per disturbi psichici
http://dati.istat.it/
Ministero della Salute, La classificazione delle malattie ICD9CM.
http://www.salute.gov.it/ricoveriOspedalieri/paginaMenuRicoveriOspedalieri.jsp?menu=classificazion
e&lingua=italiano
Riferimenti bibliografici
Roma, 26 gennaio 2015
Grazie per l’attenzione
crialesi@istat.it
Roma, 26 gennaio 2015 21

More Related Content

Similar to Roberta Crialesi, Alessandra Burgio, Francesco Grippo, Marilena Pappagallo - Morbosità e mortalità: un approccio multicausa al fenomeno della droga

Suzi Lyons - Health Research Board
Suzi Lyons - Health Research Board Suzi Lyons - Health Research Board
Suzi Lyons - Health Research Board AlcoholForum.org
 
Reduction of hospitalizations
Reduction of hospitalizationsReduction of hospitalizations
Reduction of hospitalizationsFrancesco Megna
 
NCD presentation.pptx
NCD presentation.pptxNCD presentation.pptx
NCD presentation.pptxPoojakarki10
 
Death from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in EnglandDeath from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in EnglandNHS IQ legacy organisations
 
Top Therapeutic Classes by Non-Discounted Spending
Top Therapeutic Classes by Non-Discounted SpendingTop Therapeutic Classes by Non-Discounted Spending
Top Therapeutic Classes by Non-Discounted SpendingIMS Health US
 
The drivers of public health spending: integrating policies and institutions
The drivers of public health spending: integrating policies and institutionsThe drivers of public health spending: integrating policies and institutions
The drivers of public health spending: integrating policies and institutionsOECD Governance
 
International classification of disease
International classification of diseaseInternational classification of disease
International classification of diseaseGAMANDEEP
 
10 interesting things about alcohol and other drugs that you may have missed ...
10 interesting things about alcohol and other drugs that you may have missed ...10 interesting things about alcohol and other drugs that you may have missed ...
10 interesting things about alcohol and other drugs that you may have missed ...Andrew Brown
 
ICA2014_Sarkin_Leisegang_Presentation _final
ICA2014_Sarkin_Leisegang_Presentation _finalICA2014_Sarkin_Leisegang_Presentation _final
ICA2014_Sarkin_Leisegang_Presentation _finalLee Sarkin
 
The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...Office of Health Economics
 
20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.pptShirazKhokhar1
 
Diabetes care in the time of Covid 19 2021 Prof Vinod Patel
Diabetes care in the time of Covid 19 2021 Prof Vinod PatelDiabetes care in the time of Covid 19 2021 Prof Vinod Patel
Diabetes care in the time of Covid 19 2021 Prof Vinod PatelVinod0901
 
Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...
Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...
Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...Apollo Hospitals
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)iosrphr_editor
 

Similar to Roberta Crialesi, Alessandra Burgio, Francesco Grippo, Marilena Pappagallo - Morbosità e mortalità: un approccio multicausa al fenomeno della droga (20)

Suzi Lyons - Health Research Board
Suzi Lyons - Health Research Board Suzi Lyons - Health Research Board
Suzi Lyons - Health Research Board
 
Health at a Glance: Europe 2018 - State of Health in the EU Cycle - CHARTSET
Health at a Glance: Europe 2018 - State of Health in the EU Cycle - CHARTSETHealth at a Glance: Europe 2018 - State of Health in the EU Cycle - CHARTSET
Health at a Glance: Europe 2018 - State of Health in the EU Cycle - CHARTSET
 
Reduction of hospitalizations
Reduction of hospitalizationsReduction of hospitalizations
Reduction of hospitalizations
 
Causes of death
Causes of deathCauses of death
Causes of death
 
NCD presentation.pptx
NCD presentation.pptxNCD presentation.pptx
NCD presentation.pptx
 
Death from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in EnglandDeath from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in England
 
Managing Long Term Conditions
Managing Long Term ConditionsManaging Long Term Conditions
Managing Long Term Conditions
 
COVID-19 in Italy
COVID-19 in ItalyCOVID-19 in Italy
COVID-19 in Italy
 
Top Therapeutic Classes by Non-Discounted Spending
Top Therapeutic Classes by Non-Discounted SpendingTop Therapeutic Classes by Non-Discounted Spending
Top Therapeutic Classes by Non-Discounted Spending
 
The drivers of public health spending: integrating policies and institutions
The drivers of public health spending: integrating policies and institutionsThe drivers of public health spending: integrating policies and institutions
The drivers of public health spending: integrating policies and institutions
 
International classification of disease
International classification of diseaseInternational classification of disease
International classification of disease
 
10 interesting things about alcohol and other drugs that you may have missed ...
10 interesting things about alcohol and other drugs that you may have missed ...10 interesting things about alcohol and other drugs that you may have missed ...
10 interesting things about alcohol and other drugs that you may have missed ...
 
ICA2014_Sarkin_Leisegang_Presentation _final
ICA2014_Sarkin_Leisegang_Presentation _finalICA2014_Sarkin_Leisegang_Presentation _final
ICA2014_Sarkin_Leisegang_Presentation _final
 
The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...
 
COPD
COPDCOPD
COPD
 
Sec innovacion
Sec innovacionSec innovacion
Sec innovacion
 
20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt20130909-best practices work group-presentation.ppt
20130909-best practices work group-presentation.ppt
 
Diabetes care in the time of Covid 19 2021 Prof Vinod Patel
Diabetes care in the time of Covid 19 2021 Prof Vinod PatelDiabetes care in the time of Covid 19 2021 Prof Vinod Patel
Diabetes care in the time of Covid 19 2021 Prof Vinod Patel
 
Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...
Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...
Burden of cardiovascular diseases in Indians: Estimating trends of coronary a...
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)
 

More from Istituto nazionale di statistica

More from Istituto nazionale di statistica (20)

Censimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profitCensimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profit
 
Censimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profitCensimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profit
 
Censimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profitCensimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profit
 
Censimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profitCensimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profit
 
Censimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profitCensimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profit
 
Censimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profitCensimenti Permanenti Istituzioni non profit
Censimenti Permanenti Istituzioni non profit
 
Censimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni PubblicheCensimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni Pubbliche
 
Censimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni PubblicheCensimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni Pubbliche
 
Censimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni PubblicheCensimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni Pubbliche
 
Censimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni PubblicheCensimento Permanente Istituzioni Pubbliche
Censimento Permanente Istituzioni Pubbliche
 
14a Conferenza Nazionale di Statisticacnstatistica14
14a Conferenza Nazionale di Statisticacnstatistica1414a Conferenza Nazionale di Statisticacnstatistica14
14a Conferenza Nazionale di Statisticacnstatistica14
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 
14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica14a Conferenza Nazionale di Statistica
14a Conferenza Nazionale di Statistica
 

Recently uploaded

social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajanpragatimahajan3
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...Sapna Thakur
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfchloefrazer622
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Disha Kariya
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...fonyou31
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 

Recently uploaded (20)

social pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajansocial pharmacy d-pharm 1st year by Pragati K. Mahajan
social pharmacy d-pharm 1st year by Pragati K. Mahajan
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
BAG TECHNIQUE Bag technique-a tool making use of public health bag through wh...
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 
Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
Ecosystem Interactions Class Discussion Presentation in Blue Green Lined Styl...
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 

Roberta Crialesi, Alessandra Burgio, Francesco Grippo, Marilena Pappagallo - Morbosità e mortalità: un approccio multicausa al fenomeno della droga

  • 1. Morbosità e mortalità: un approccio multicausa al fenomeno della droga Roberta Crialesi, Alessandra Burgio, Francesco Grippo, Marilena Pappagallo Migliorare la comprensione del fenomeno droga: quali dati per le politiche Roma, 26 gennaio 2015 Istat, Aula Magna
  • 2. • La riduzione della perdita di vite umane causata dal consumo di stupefacenti è una priorità strategica delle politiche di lotta alla droga e uno degli obiettivi di salute pubblica dell’Unione europea • Valutare scientificamente le conseguenze dirette e indirette dell’uso di droghe non è semplice. Nel corso degli ultimi anni, le politiche di riduzione del danno hanno stimolato l’adozione di approcci basati su dati incontrovertibili. • Uno degli approcci più innovativi per fornire un quadro realistico dell’impatto delle droghe sulla salute della popolazione italiana è quello basato sulla comorbidity e sulla cause multiple di decesso • Occorrono indicatori innovativi per misurare, in modo più accurato, la reale dimensione del fenomeno estendendo l’osservazione a tutti i casi, direttamente o indirettamente, collegati all’abuso di droghe. Elementi chiave della strategia europea di riduzione del danno Roma, 26 gennaio 2015 2
  • 3. Obiettivi dello studio • Analizzare la mortalità indotta da droga e l’ospedalizzazione dei pazienti tossicodipendenti per descrivere l’evoluzione nel tempo dei principali indicatori secondo il genere, l’età e le macro aree di residenza • Utilizzare l’approccio per cause multiple per  fornire nuovi indicatori basati su tutte le informazioni riportate sia nel certificato di morte sia nelle SDO valutare statisticamente le associazioni tra l’abuso di droga e altre condizioni patologiche 3Roma, 26 gennaio 2015
  • 4. In Italy an average of 4,2 conditions are reported. The International Classification of Diseases (Icd) contains instruction for coding each condition and for the selection of the Underlying cause. Causes of Death Register • Refers to all cases occurred in Italy • Certifying physician reports a sequence of conditions leading to death on the death form: Part 1: Line a (Underlying cause) ___________________________________ Line b (complications) ___________________________________ Line c ___________________________________ Line d ___________________________________ Part 2 (Other causes ___________________________________ Contributing) ___________________________________ Hiv infection Kaposi’s sarcoma Heroin dependency for many years Pneumonia Septicemia Coding Each Condition: Icd-10 codes B24 C46 J18.9 A41.9 F11.2 SELECTION Process UC: B24 HIV disease In Italy, until 2003 data only this information was published Traditionally, final statistics are based on UNDERLYING CAUSE OF DEATH One for each record defined as: (a) the disease of injury which initiated the train of events leading directly to death, or (b) the circumstances of the accident or violence which produced the fatal injury Since 2003 data also this information is available MULTIPLE CAUSES OF DEATH Specimen based on Istat D4 4
  • 5. Drug-induced mortality: selection of Icd codes (EMCDDA selction B for international comparison and time series) ICD-10: years 2003, 2006-2011 Mental and behavioural disorders due to psychoactive substance use F11: opioids; F12: cannabinoids, F14: cocaine; F15: other stimulants, including caffeine; F16: hallucinogens; F19: other psychoactive substances Accidental poisoning X421): narcotics and psychodysleptics [hallucinogens], not elsewhere classified; X412antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified Intentional self-poisoning X621): narcotics and psychodysleptics [hallucinogens], not elsewhere classified; X612): antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified. Poisoning undetermined intent Y121): psychodysleptics [hallucinogens], not elsewhere classified, undetermined intent; Y112): antiepileptic, sedative-hypnotic, antiparkinsonism and psychotropic drugs, not elsewhere classified, undetermined intent. 1) in combination with the T-codes: T40.0-9: Poisoning by narcotics and psychodysleptics [hallucinogens]; 2) in combination with T code: T43.6 Poisoning by psychotropic drugs, Psychostimulants with abuse potential. 5
  • 6. Numero di decessi droga-indotti avvenuti in Italia registrati nel database ISTAT sulle cause di morte (popolazione presente). Anni 1980-2011 Confronto con Emcdda 6 Numerodidecessi
  • 7. Trends per genere ed età Anni 1992-2011
  • 8. Mortalità indotta da droghe per macroarea e anno di decesso. Poolazione residente, anni 1992-2010. Tassi std.di mortalità per 1.000.000 abitanti Geografia
  • 9. Underlying cause of death Multiple cause of death Ratio Multiple/ Underlyingdeaths crude rate standardiz ed rate deaths crude rate standardiz ed rate 15-44 year 605 0,87 816 1,18 1,3 45-54 175 0,67 398 1,53 2,3 55-64 33 0,15 79 0,36 2,4 Total 15- 64 males 692 1,19 1,17 1.115 1,91 1,84 1,6 females 121 0,21 0,20 178 0,30 0,29 1,5 Total 813 0,69 0,69 1.293 1,10 1,07 1,6 Drug-related deaths in selected age groups as underlying and multiple cause. Years 2009-2011 Total 2006-2008 1.193 1,03 1,03 1.606 1,39 1,36 1,3 9
  • 10. Methods Age-standardized relative risk (RR) was used to measure association among drug related cause and the other conditions reported on the death certificate The relative risk can be seen as a measure of the strength of association of a certain cause with drug- related condition. )(ln96.1ln)(ln%95 RRSERRRRCI  Assumed that RR is approximately log-normally distributed: where Proportion of estimated deaths with a specific condition A among those WITH mention of drug-related cause Proportion of estimated deaths with a specific condition A among those WITHOUT mention of drug-related cause Cause A mentioned Cause A not mentioned Mention of drug-related cause Without mention of drug- related cause dADˆ Ad Dˆ Ad Dˆ Ad Dˆ dD d D Ad dA d Ad d dA p p D D D D RR ˆ ˆˆ / ˆ  Ad Ad dA dA D p D p RRES ˆ )ˆ1( ˆ )ˆ1( )(ln     Associations of conditions with drug-related causes.
  • 11. Associations of conditions with drug-related causes. 1.293 cases, Italy 2009-2011 Icd10 Condition Prevalence in drug users deaths Prevalence in non-drug users deaths Age- standardized RR CI95% Certificates mentioning the condition among drug users deaths A00-B99 Infectious and parasitic diseases 23,8 9,4 3,4 3,2-3,7 308 B20-B24 AIDS 7,1 1,2 5,9 4,8-7,2 92 B15-B19, B94.2 Viral hepatitis 18,2 2,5 10,7 9,7-11,8 235 F01-F99 Mental and behavioural disorders (excluded those included in EMCDDA) 14,2 4,0 6,8 6,2-7,5 184 F10 Mental and behavioural disorders due to use of alcohol 9,6 0,9 17,5 15,4-20,0 124 I00-I99 Diseases of the circulatory system 40,4 48,0 1,1 1,0-1,2 522 I33 Acute and subacute endocarditis 0,9 0,1 7,0 3,9-12,6 11 I38 Endocarditis, valve unspecified 1,2 0,3 2,0 1,0-3,9 15 J00-J99 Diseases of the respiratory system 32,6 24,6 1,2 1,1-1,3 422 K00-K92 Diseases of the digestive system 22,1 16,1 1,8 1,6-1,9 286 K70, K73-K74 Cirrhosis, fibrosis and chronic hepatitis 16,2 6,2 3,6 3,2-4,0 209 K70 Alcoholic liver disease 3,3 1,3 2,7 2,0-3,6 43 K73 Chronic hepatitis, not elsewhere classified 1,1 0,2 19,5 14,3-26,7 14 R00-R99 Symptoms signs and ill-defined causes 38,6 33,6 1,1 1,1-1,2 499 R75 Laboratory evidence of human immunodeficiency virus [HIV] 1,3 0,1 9,1 5,4-15,2 17 V00-Y99 External causes of death (excluded those included in EMCDDA) 52,6 14,0 2,4 2,2-2,6 680 Roma, 26 gennaio 2015 12
  • 12. Schede di Dimissione Ospedaliera (SDO) • La diagnosi principale è utilizzata per la costruzione di indicatori statistici (come per le cause di morte) •International Classification of Diseases 9th Revision, Clinical Modification (ICD9CM) •Diagnosi principale e fino a 5 Diagnosi secondarie • In media sono riportate 2.5 diagnosi per ricoveri ordinary e 1,6 per day hospital • Le Diagnosi sono codificate direttamente in ospedale DIAGNOSI PRINCIPALE definita come la malattia che alla dimissione viene identificata come la principale responsabile del trattamento e delle procedure fornite dall’ospedale. DIAGNOSI SECONDARIA Definite come quelle condizioni che coesistono al momento del ricovero o che si sviluppano in seguito a tale momento e che influenzano il trattamento ricevuto e/o la durata della degenza Co-morbidity approach 13
  • 13. Number of hospital discharges for drug-related disorders 0 2,000 4,000 6,000 8,000 10,000 12,000 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 • From 10,968 in 1999 to 5,857 in 2012 (-46.6%) • Sharp decrease between 1999 and 2003, smoothed afterwards Crude rates (a) Standardized rates (a) 1999 19.3 18.5 2012 9.8 10.2 (a) per 100,000 residents Number of patients treated in outpatient facilities for drug-related disorders 14
  • 14. Trends by age Age-specific hospitalization rates for drug-related disorders per 100,000 residents • Higher hospitalization rates in the age group 25-44 years • followed by 15-24 years before 2009 and 45-54 years too afterwards • Age gaps reduced over time Roma, 26 gennaio 2015 15
  • 15. Drug-related hospitalizations 15-64 years. Main diagnosis and All diagnosis. Years 2006-2008, 2009-2011 Main diagnosis All diagnosis Age discharges crude rate discharges crude rate 2006-2008 15-44 13,834 19.3 40,721 56.8 2.9 45-54 2,222 9.1 8,625 35.4 3.9 55-64 811 3.8 2,653 12.4 3.3 2009-2011 15-44 11,801 16.8 32,611 46.3 2.8 45-54 3,265 12.4 9,727 36.8 3.0 55-64 1,356 6.1 3,041 13.6 2.2 Ratio All/Main 15-64 years Main diagnosis All diagnosis Gender discharges crude rate standardized rate discharges crude rate standardized rate 2006-2008 males 11,407 19.4 21.7 35,617 60.6 66.7 3.1 females 5,460 9.3 10.4 16,382 27.9 30.8 3.0 total 16,867 14.4 16.1 51,999 44.2 48.9 3.1 2009-2011 males 9,831 16.6 18.6 30,663 51.6 57.3 3.1 females 6,591 11.0 12.2 14,716 24.7 27.2 2.2 total 16,422 13.8 15.4 45,379 38.1 42.3 2.8 Ratio All/Main • All diagnosis:  Decreasing std rates…  …due to the decrease in the age group 15-44 years…  …while rates slightly increase after 45 years of age • Hospitalizations with mention of drug use or poisoning is 2.8 higher than the number based on the Main diagnosis • Gender gap: std rates higher for men (1.5 times for main diag., 2.1 times for all diag.) 16
  • 16. Drug-related hospitalizations by substance (dependence, abuse or poisoning) 15-64 years - All diagnosis. Ratios All diagnosis / Main diagnosis 0 10 20 30 40 50 2006-2008 2009-2012 Mixed or unspecified substances Cannabis, Amphetamine and other psychostimulant Cocaine Opioid type (Heroin, Methadone, Opium, etc.) 19,773 9,130 5,374 17,722 15,908 7,803 5,461 16,207 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2006-2008 2009-2012 Mixed or unspecified substances Cannabis, Amphetamine and other psychostimulant Cocaine Opioid type (Heroin, Methadone, Opium, etc.)38.0% 35.1% 17.6% 17.2% 10.3% 12.0% 34.1% 35.7% Standardized hospitalization rates for drug-related disorders per 100,000 residents (absolute numbers in the bars) Ratios Males / Females 17
  • 17. Associations of conditions with drug-related diagnosis (1) ICD9CM code Condition Prevalence in hospitalizations for drug disorders Prevalence in hospitalizations NOT for drug disorders Age standardized RR CI95% Hospital discharge records with mention of the condition among hospitalizations for drug disorders INFECTIOUS AND PARASITIC DISEASES (001-139) 042 Human immunodeficiency virus [HIV] disease 7.77 0.53 13.08 12.63-13.53 3,528 070 Viral hepatitis 11.38 0.76 12.55 12.19-12.91 5,162 112 Candidiasis 1.51 0.10 15.11 13.98-16.34 684 MENTAL DISORDERS (290-319) 295 Schizophrenic disorders 4.86 0.73 5.57 5.32-5.82 2,204 296 Affective psychoses 10.70 0.93 11.51 11.20-11.83 4,854 298 Other nonorganic psychoses 3.65 0.29 11.11 10.55-11.70 1,656 300 Neurotic disorders 7.75 0.87 11.42 11.10-11.74 3,518 301 Personality disorders 19.37 0.54 28.92 28.28-29.58 8,790 303 Alcohol dependence syndrome 8.31 0.33 21.81 21.08-22.57 3,772 307 Special symptoms or syndromes, not elsewhere classified 3.35 0.27 17.08 16.36-17.82 1,520 309 Adjustment reaction 1.63 0.13 12.81 11.91-13.77 741 Roma, 26 gennaio 2015 18
  • 18. Associations of conditions with drug-related diagnosis (2) ICD9CM code Condition Prevalence in hospitalizations for drug disorders Prevalence in hospitalizations NOT for drug disorders Age standardized RR CI95% Hospital discharge records with mention of the condition among hospitalizations for drug disorders DISEASES OF THE NERVOUS SYSTEM AND SENSE ORGANS (320-389) 345 Epilepsy 1.68 0.63 2.57 2.39-2.76 762 346 Migraine 12.78 0.19 100.07 97.91-102.27 5,799 DISEASES OF THE CIRCULATORY SYSTEM (390-459) 401 Essential hypertension 3.12 4.70 1.33 1.29-1.38 1,417 DISEASES OF THE RESPIRATORY SYSTEM (460-519) 486 Pneumonia, organism unspecified 1.00 0.26 3.84 3.50-4.21 456 491 Chronic bronchitis 1.20 1.09 1.68 1.57-1.80 545 518 Other diseases of lung 2.34 1.16 2.24 2.12-2.37 1,062 DISEASES OF THE DIGESTIVE SYSTEM (520-579) 571 Chronic liver disease and cirrhosis 6.27 1.90 3.35 3.23-3.47 2,845 SYMPTOMS, SIGNS, AND ILL-DEFINED CONDITIONS (780-799) 780 General symptoms 2.44 1.39 1.84 1.74-1.95 1,107 INJURY AND POISONING (800-999) 965 Poisoning by analgesics, antipyretics, and antirheumatics 2.31 0.01 313.35 288.93-339.84 1,050 969 Poisoning by psychotropic agents 1.38 0.05 28.02 25.79-30.45 627 SUPPLEMENTARY CLASSIFICATION OF FACTORS INFLUENCING HEALTH STATUS AND CONTACT WITH HEALTH SERVICES (V01-V82) V02 Carrier or suspected carrier of infectious diseases 1.12 0.18 5.76 5.25-6.31 510 Roma, 26 gennaio 2015 19
  • 19. 20 Istat, Navigando tra le fonti demografiche e sociali, 2009 http://www3.istat.it/dati/catalogo/20100325_01/Navigando_tra_le_fonti_demografiche_sociali.pdf WHO. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Geneva: WHO; 1992. Emcdda methods and definitions http://www.emcdda.europa.eu/stats07/DRD/methods Istat. Cause di morte. Anno vari. http://www.istat.it/it/archivio/ Emcdda, Data, drug related death and mortality http://www.emcdda.europa.eu/stats/archive. Istat. Cause multiple di morte. Anno 2008. http://www.istat.it/it/archivio/66021 Istat, I.Stat, Salute e sanità, Ricorso ai servizi sanitari, Ospedalizzazione per disturbi psichici http://dati.istat.it/ Ministero della Salute, La classificazione delle malattie ICD9CM. http://www.salute.gov.it/ricoveriOspedalieri/paginaMenuRicoveriOspedalieri.jsp?menu=classificazion e&lingua=italiano Riferimenti bibliografici Roma, 26 gennaio 2015